c9c39051-4f42-45fd-9781-75f02df69605 - samples

NIAID Data Ecosystem2026-03-14 收录

乳腺癌辅助治疗临床试验

HER2靶向治疗疗效评估

数据链接：

https://www.omicsdi.org/dataset/ega/EGAD00001008785 数据链接链接失效反馈

官方服务：

资源简介：

Clinical data for KATHERINE: Clinical data include Treatment Arm, Invasive Disease Free Survival (IDFS), Clinical Stage at Presentation, Hormone Receptor Status, Preoperative HER2 Directed Therapy, Pathological Node.EGA dataset EGAD00001008785

创建时间：

2023-02-08

Metadata record for the article: Effect of Metformin versus Placebo on Metabolic Factors in the MA.32 Randomized Adjuvant Breast Cancer Trial

乳腺癌辅助治疗临床试验

药物代谢因素分析

Summary This metadata record provides details of the data supporting the claims of the related article: “Effect of Metformin versus Placebo on Metabolic Factors in the MA.32 Randomized Adjuvant Breast

Figshare2021-05-13 更新20

Summary of included studies evaluating the prognostic value of ctDNA mutation status in HER2-targeted therapy for breast cancer.

乳腺癌预后生物标志物分析

HER2靶向治疗疗效评估

This table summarizes the key characteristics of the 12 included studies investigating the association between ctDNA mutation status and PFS in patients receiving anti-HER2 therapies. Data include pub

Zenodo2025-06-30 更新00

Dataset from PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

乳腺癌辅助治疗临床试验

肿瘤基因组亚组分析

Please note, this study is only available to request by PALLAS investigators. This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the additi

NIAID Data Ecosystem00

UNIRAD (UK) - Sample collection

乳腺癌辅助治疗临床试验

ER+/HER2-乳腺癌

UNIRAD: Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- prima

SAIL Databank20

The tumor immune microenvironment and therapeutic efficacy of trastuzumab deruxtecan in gastric cancer

肿瘤免疫微环境分析

HER2靶向治疗疗效评估

Trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody-drug conjugate with a topoisomerase I inhibitor connected by a cleavable linker, has been approved for patients with HER2-positive gastric or gast

NIAID Data Ecosystem00

c9c39051-4f42-45fd-9781-75f02df69605 - samples

资源简介：

相关数据集